Bejelentkezés Regisztrálj ingyen

Novabay Pharmaceuticals Inc Bevétel Y / Y

Mi az Novabay Pharmaceuticals Inc Bevétel Y / Y?

A Bevétel Y / Y az Novabay Pharmaceuticals Inc - -20.92%

Mi a Bevétel Y / Y meghatározása?

Az elmúlt 3 évben az éves bevételnövekedés a bevételek növekedése az elmúlt 3 év átlagában az elmúlt 3 évben.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Bevétel Y / Y a Health Care szektor a NYSEMKT-on cégekben a Novabay Pharmaceuticals Inc -hoz képest

Mit csinál Novabay Pharmaceuticals Inc?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

bevétel y / y -hoz hasonló cégek Novabay Pharmaceuticals Inc